Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 8/3075% above fair value
$3.52−0.26 (-6.88%)
Close on Nov 12, 2026Market cap $280.91MP/E –Yield –
Prelude Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Prelude Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$65.81M. For fiscal 2025 it was -$102.86M. The highest annual figure on record is -$27.73M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$102.86M | – |
| FY2024 | Dec 31, 2024 | -$137.94M | – |
| FY2023 | Dec 31, 2023 | -$131.11M | – |
| FY2022 | Dec 31, 2022 | -$122.22M | – |
| FY2021 | Dec 31, 2021 | -$112.82M | – |
| FY2020 | Dec 31, 2020 | -$58.22M | – |
| FY2019 | Dec 31, 2019 | -$27.73M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.34M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$36.71M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.84M | – |
| Q4 FY2022 | Dec 31, 2022 | -$33.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.14M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$32.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$30.57M | – |
| Q2 FY2021 | Jun 30, 2021 | -$27.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.81M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.97M | – |
See a number that looks wrong?